Gubra starts first-in-human Phase 1/2a trial of obesity drug candidate GUB-UCN2

• Gubra started a first-in-human Phase 1/2a trial of obesity candidate GUB-UCN2, with the first participant completing the first visit.
• Results have not been presented; initial safety, tolerability, and pharmacokinetic readouts from the single-dose portion are expected in H1 2027.
• The study will assess early signals on body composition, with emphasis on preserving or improving muscle volume and function alongside weight-loss treatment.
• About 188 healthy volunteers and people with obesity will be enrolled, testing GUB-UCN2 alone or combined with incretin-based therapy.
• Preclinical findings indicated fat-mass reduction with muscle-mass gains, including prevention or reversal of lean-mass loss seen with GLP-1 therapies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gubra A/S published the original content used to generate this news brief on July 28, 2026, and is solely responsible for the information contained therein.